RT Book, Section A1 Papadakis, Maxine A. A1 McPhee, Stephen J. A1 Rabow, Michael W. A1 McQuaid, Kenneth R. SR Print(0) ID 1193123588 T1 Geriatric Disorders Year in Review T2 Current Medical Diagnosis & Treatment 2023 YR 2023 FD 2023 PB McGraw-Hill Education PP New York, NY SN 9781264687343 LK accessmedicine.mhmedical.com/content.aspx?aid=1193123588 RD 2024/03/28 AB Aducanumab, a monoclonal antibody that targets amyloid-beta protein and promotes its clearance from the brain, became the first new drug approved by the FDA for the treatment of Alzheimer disease since 2003.